Y10S 530/836
Mucus
Official title: Mucus; mucous glands; bursa; arthral fluid; spinal fluid
Y10S530/836 (Mucus) appears on 7 US grants and 3 published applications in this corpus.
Search patents in Y10S- Granted patents
- 7
- Published applications
- 3
- Assignees
- 7
- Inventors
- 14
- Latest grant
- 6 Mar 2012
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Process for determining tissue product break-through6 Mar 2012US 8,127,601 B2The Procter & Gamble Company
- Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions3 Jul 2001US 6,255,281 B1Claragen, Inc. and U.S. Government
- Detection and treatment of ulcerative colitis8 Mar 1994US 5,292,667 AThe General Hospital Corporation
- Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen1 Oct 1991US 5,053,489 ADana-Farber Cancer Institute, Inc.
- Mitogenic spinal cord growth factor8 Mar 1983US 4,376,071 AResearch Corporation
- Process for determining tissue product break-through16 Dec 2010US 2010/0313649 A1The Procter & Gamble Company
- Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions13 Mar 2008US 2008/0064633 A1
- Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions21 Nov 2002US 2002/0173460 A1Claragen, Inc.
Most cited
By later US patents
- Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen51US 5,053,489 ADana-Farber Cancer Institute, Inc. · 1991
- Process for extracting and processing glycoproteins, mucopolysaccharides and accompanying substances36US 4,108,849 A1978
- Ubiquitary tissue protein PP.sub.812US 4,301,064 ABehringwerke Aktiengesellschaft · 1981
- Mitogenic spinal cord growth factor9US 4,376,071 AResearch Corporation · 1983
- Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions7US 6,255,281 B1Claragen, Inc. and U.S. Government · 2001